The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure
Open accessAbstract
The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double‐blind, placebo‐controlled, multicenter study assessed change from baseline in mean 24‐hour ambulatory systolic blood pressure (SBP) following 6 weeks of treatment. Patients with primary hypertension ( n =1275) and baseline 24‐hour mean ambulatory systolic pressure ≥130 mm Hg and ≤170 mm Hg were studied; 142 received placebo and the remainder received 20 mg, 40 mg, or 80 mg AZL‐M or 40 mg OLM‐M. Mean age of participants was 58±11 years, baseline mean 24‐hour SBP was 146 mm Hg. Dose‐dependent reductions in 24‐hour mean SBP at study end occurred in all AZL‐M groups. Reduction in 24‐hour mean SBP was greater with AZL‐M 80 mg than OLM‐M 40 mg by 2.1 mm Hg (95% confidence interval, −4.0 to −0.1; P=.038), while AZL‐M 40 mg was noninferior to OLM‐M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL‐M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM‐M. J Clin Hypertens (Greenwich). 2011;13:81–88. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, 24-hour ABPM studies demonstrate that azilsartan medoximil provides on average an additional 4 to 8 mm Hg further SBP reduction over other ARBs (eg, valsartan and olmesartan) or the ACE inhibitor ramipril.381–383”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [382]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Pitt, B., Segal, R., Martínez, F. A., Meurers, G., Cowley, A. J., Thomas, I., DEEDWANIA, P. C., Ney, D. E., Snavely, D. B., & Chang, P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,660
Blood Pressure Lowering Treatment Trialists’ Collaboration (2008) · BMJ · doi:10.1136/bmj.39548.738368.be · Cited by 739
Cited by
Sorted by citations
Items 101–143 of 143
Miyoshi, T., Onoue, G., & Ito, H. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3723 · Cited by 2
“According to previous studies of azilsartan [4-6] and a fixed-dose tablet of an ARB and a calcium channel blocker (CCB) or an ARB and a diuretic at the usual dose in Japan [11-14], we hypothesized that azilsartan at 40 mg is more efficacious than these combination therapies.”
BackgroundMethodDarwish, H. W., Bakheit, A. H. H., Abdelhameed, A. S., & Mustafa, B. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i5.15 · Cited by 2
“Despite the availability of antihypertensive agents, hypertension remains inadequately controlled, with slightly less than half of patients who receive medication successfully achieving adequate blood pressure (BP) [2].”
BackgroundKamada, T., Hayashi, M., Fujiwara, W., Yoshikawa, D., Mukaide, D., Sugishita, Y., Yoshinaga, M., Itoh, T., 横井, 博., Ishii, J., et al. (2016) · Drug and Chemical Toxicology · doi:10.1080/01480545.2016.1188301 · Cited by 2
“E-mail: izawa@fujita-hu.ac.jp lowering BP than other ARBs at their maximum approved doses in a series of comparative studies (Bakris et al., 2011; Rakugi et al., 2013; White et al., 2011).”
BackgroundEfficacy and Safety of a Single-Pill Fixed-Dose Combination of Azilsartan and Amlodipine
Motozato, K., Miura, S., Shiga, Y., Kusumoto, T., & Saku, K. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2768w · Cited by 2
“Azilsartan medoxomil and azilsartan have been reported to have greater antihypertensive effects than other ARBs [5-8].”
BackgroundАттенто — нове слово в лікуванні артеріальної гіпертензії
Sirenko, Y., & Rekovets, О. L. (2018) · HYPERTENSION · doi:10.22141/2224-1485.1.57.2018.125494 · Cited by 2
New Drugs and Interventional Strategies for the Management of Hypertension
Christophides, T., Somaschini, A., Demarchi, A., Cornara, S., Androulaki, M., & Androulakis, E. S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201106091527 · Cited by 2
Selective formation of a phenathridine derivative by photodegradation of azilsartan
Yoshikawa, T., Hayashi, N., Hatta, N., & Yokota, M. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128011 · Cited by 2
Bhajni, E., Sehgal, V. K., Kumar, A., & Sehgal, A. (2020) · International Journal of Medical and Dental Sciences · doi:10.18311/ijmds/2020/24723 · Cited by 2
Morales-Villegas, E., Alcocer-Díaz-Barreiro, L., & Moreno-Virgen, G. (2021) · Medical Research Archives · doi:10.18103/mra.v9i10.2555 · Cited by 2
Goldenberg, R., Cheng, W., Bell, A., Burrows, M., Blavignac, J., Paron, E., Fils‐Aimé, N., & Barakat, M. (2020) · Journal of Hypertension and Management · doi:10.23937/2474-3690/1510053 · Cited by 1
“In 2016, Health Canada also approved a fixed dose combination of azilsartan medoxomil with chlorthalidone (AZI/CHL) [25] for the treatment of severe HTN [28,29].”
BackgroundInfluentialZhu, L., Wei, G., Xiao, Q., Chen, Q.-L., Zhao, Q., Li, X., Pan, L., & Xiong, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1383217 · Cited by 1
Fricke, U., & Schwabe, U. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_2 · Cited by 1
THE EVALUATION OF TOPOGRAPHY BORRELIA BURGDORFERI BY ATOMIC FORCE MICROSCOPE (AFM)
Tokarska-Rodak, M., & Kozioł-Montewka, M. (2016) · Health Problems of Civilization · doi:10.5114/hpc.2015.57127 · Cited by 1
“…the clinical measurement of blood pressure and diurnal blood pressure monitoring showed statistically significant superiority in reducing BP compared to valsartan (White et al. 2011, Sica et al. 2011), candesartan (Rakugi et al. 2012) and olmesartan therapy (White et al. 2011, Bakris et al. 2011).”
ResultCombination Therapy in Hypertension Treatment
Oliva, R., & Bakris, G. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3691-1_5 · Cited by 1
Self-citationThanaprirax, P., Nata, N., Supasyndh, O., & Satirapoj, B. (2023) · Journal of Southeast Asian Medical Research · doi:10.55374/jseamed.v7.156 · Cited by 1
“This study provided evidence of potent blood pressure and albuminuria lowering effects with azilsartan among patients with CKD. Azilsartan is a new ARB exhibiting a higher affinity and selectively on AT1 receptors than other ARBs(12) and azilsartan provides significantly more effectiveness in lowering blood pressure t…”
BackgroundBorodulina, A. D., Kutumova, E. O., Израйлевна, Л. Г., & Kolpakov, F. (2023) · Mathematical Biology and Bioinformatics · doi:10.17537/2023.18.228 · Cited by 1
Gilarevsky, S. R. (2024) · Kardiologiia · doi:10.18087/cardio.2024.4.n2646 · Cited by 1
Efectividad del tratamiento antihipertensivo y control de la hipertensión arterial: ¿es mejorable?
Sierra, C., & Ruilope, L. M. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.04.044 · Cited by 1
Unique mode of binding between angiotensin II type 1 receptor and its blockers
Matsuo, Y., Suematsu, Y., Tomita, S., Tashiro, K., Kuwano, T., Kitajima, K., & Miura, S. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1545851 · Cited by 1
“Equilibrium binding kinetics were determined (13,14).”
MethodAzilsartan medoxomil: opportunities and prospects in diabetes mellitus
Kochergina, A. M., & Барбараш, О. Л. (2021) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2021-27-2-247-254 · Cited by 1
Афанасьевна, Н. В., Petrichko, T. A., Chazova, I. E., & Zhernakova, Y. V. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.12.201270 · Cited by 1
Martynyuk, T. V., & Chazova, I. E. (2017) · Systemic Hypertension · doi:10.26442/2075-082x_14.2.45-50 · Cited by 1
Newer Angiotensin Receptor Blockers
Iyengar, S. S., & Saleha, N. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-030-95734-6_23 · Cited by 1
Manolis, A. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734299250.793571584 · Cited by 1
Olmesartán: evidencia y práctica clínica
Morales‐Olivas, F. J. (2013) · Hipertensión y Riesgo Vascular · doi:10.1016/s1889-1837(13)70014-x
NEW ASPECTS IN THE TREATMENT OF HYPERTENSION
Meretskyi, V. (2016) · Health Problems of Civilization · doi:10.5114/hpc.2015.57128
“…the clinical measurement of blood pressure and diurnal blood pressure monitoring showed statistically significant superiority in reducing BP compared to valsartan (White et al. 2011, Sica et al. 2011), candesartan (Rakugi et al. 2012) and olmesartan therapy (White et al. 2011, Bakris et al. 2011).”
ResultAzilsartan: from bench to bedside
Prajapati, H. K., Barkate, H. V., & Sharma, R. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0308-3
“In other studies, response rates were 57 % with azilsartan 80 mg/day compared with 53 % with olmesartan 40 mg/day [16], and 59 % with azilsartan 80 mg/day compared with 47 % with valsartan 320 mg/day [17].”
BackgroundMethodAzilsartan Medoxomil:Angiotensin Receptor Blocker in the Treatment of Hypertension
Sood, M. M. (2013) · International Journal of Medical and Dental Sciences · doi:10.19056/ijmdsjssmes/2013/v2i1/86746
“[12] Azilsartan (40mg and 80mg) showed significantly greater reduction in mean systolic blood pressure as compared to angiotensin converting enzyme inhibitor rampril 10mg daily [10] and also valsartan 320 mg.”
MethodZaman, Z. A., & Sinha, H. K. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20173733
“Azilsartan 40-80mg per day lowered systolic and diastolic BP significantly more than candesartan cilexetil (12mg).(31) The result regarding the binding affinity of azilsartan and candesartan demonstrated that these ARBs interact with the same sites in the AT1 receptor [(Tyr (113), Lys (199), and Gln (257)] The hydroge…”
BackgroundIvanova, M. D., Skalii, N. N., & Ivanov, D. D. (2017) · KIDNEYS · doi:10.22141/2307-1257.0.2.12.2015.75372
Das, P. (2020) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v8i3.97
(2020) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2020/9.12.5320
Кобалава, Ж. Д., Safarova, A. F., Gudieva, K., Маркова, М. А., & Petrosyan, A. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-04-01
r (2012) · Der Hausarzt · doi:10.1007/s15200-012-0156-8
«New» molecules composed of rational combinations of antihypertensive drugs: issues of choice
Кislyak, O. A., & Chervyakova, Y. B. (2015) · Systemic Hypertension · doi:10.26442/sg29114
Impact of clinical pharmacy guidance on valsartan recall management: a retrospective review
Sims, K., Zhu, W., & Zaiken, K. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00918-6
Луконин, И. А., Skibitsky, V. V., Вадимовна, Ф. А., Витальевич, С. А., & Antipov, I. A. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-1-68-74
Валерьевна, Ж. Ю., & Chazova, I. E. (2023) · Systemic Hypertension · doi:10.38109/2075-082x-2023-3-27-37
Nedogoda, S. V., Salasyuk, A. S., Barykina, I. N., Lutova, V. O., & Popova, E. A. (2023) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2023-29-5-518-534
Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone
Смирнова, М. Д., Фофанова, Т. В., & Ageev, F. T. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6190
Liu, J., Geng, J., Liu, J., 蕾, 胡., Huimin, D., Hung, I. J., & Fang, J. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00813-9
Hikal, H., Glushachenko, O. O., Markin, R., & Syrotychuk, O. (2026) · Research Square · doi:10.21203/rs.3.rs-10832498/v1
Metadata
- Authors
- Bakris, G. L., Sica, D., Weber, M., White, W. B., Roberts, A., Perez, A., Cao, C., & Kupfer, S.
- Affiliations
- University of Connecticut (US)
- State University of New York (US)
- Corresponding author
- Bakris, George L.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2011-01-27
- Volume
- 13
- Issue
- 2
- Pages
- 81-88
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- PMC
- PMC8673073
- OpenAlex
- W2077469844
- Cited by
- 143
- References
- 24
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 13 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 16 · 2015: 7 · 2014: 5 · 2013: 19 · 2012: 21
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Hypertension (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- PepsiCo
- Gilead Sciences
- FibroGen
- Savient Pharmaceuticals
- Daiichi-Sankyo
- Astellas Pharma
- Servier
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- azilsartan medoxomil, olmesartan medoxomil, angiotensin receptor blockers, antihypertensive efficacy, essential hypertension, 24-hour ambulatory blood pressure, systolic blood pressure, dose-response relationship, drug safety, non-inferiority
- MeSH terms
- Aged, Argentina, Benzimidazoles, Blood Pressure, Blood Pressure Determination, Double-Blind Method, Female, Humans, Hypertension, Imidazoles, Male, Mexico, Middle Aged, Oxadiazoles, Peru, Tetrazoles, United States, Treatment Outcome, Blood Pressure Monitoring, Ambulatory, Racial Groups, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
